Shalby Q1 FY27 Earnings Call — Analysis (NSE: SHALBY)

Shalby Q1 FY27 consolidated revenue rises 11.6% YoY to ₹338.6 Cr; MedTech EBITDA turns positive for the fourth straight quarter, while hospital margins dip on doctor ramp-ups and payer mix shift, with management guiding hospital EBITDA margin recovery to >20% for FY27.

19 Aug 2026 · Analysis by Alpha Inflection

Result quality: watch — Margin pressure. Management sentiment: optimistic.

The take

Q1FY27 Consolidated Revenue ₹338.6 Cr ( +11.6% YoY ) . New guidance — FY27 hospital standalone ebitda marg… upward of 20% . New story: Hospital margin recovery via occupancy and TPA .

Results

Consolidated revenue ₹338.6 Cr (+11.6% YoY), EBITDA ₹49 Cr (+1% YoY), PAT ₹10.5 Cr (vs ₹7.7 Cr); hospital standalone revenue ₹259 Cr (+7% YoY), EBITDA margin contracted to 18.4% from 21.6%; MedTech consolidated revenue ₹47 Cr (+53% YoY) with EBITDA positive at ₹1.7 million.

Financial highlights

Guidance

Management expects hospital standalone EBITDA margin to reach upward of 20% in FY27, Shalby International to turn PBT positive in 6-9 months, MedTech to achieve double-digit EBITDA margin after cost-cutting projects, and consolidated ROCE to improve to 11-13% in 1-2 years.

What management committed to

• [Shalby hospital standalone] EBITDA margin to be upward of 20% on a whole-year basis for FY27. — upward of 20%, FY27
• [Shalby International (Gurgaon unit)] occupancy to touch 30% or up from Q3 or Q4 FY27 onwards. — 30% or up, Q4FY27
• [Shalby International (Gurgaon unit)] will achieve PBT positive by end Q3 FY27 or within 6-9 months. — PBT positive, Q4FY27
• [MedTech] will achieve double-digit EBITDA margin after cost-cutting initiatives are fully implemented; the initiatives will reduce [MedTech] cash flow requirement by ₹3 Cr/month immediately and another ₹3 Cr/month by Q4 FY27. — double-digit EBITDA margin; ₹3 Cr/month reduction immediately, another ₹3 Cr/month by Q4, Q4FY27
• [Consolidated] ROCE to reach 11-13% within 1 to 2 years from now. — 11% to 13%, FY28
• [Consolidated] net debt will not increase; it will remain stable or on a reducing trend in coming quarters. — stable or reducing, Q3FY27
• [MedTech] gross margins are expected to increase about 100 to 200 basis points each quarter from here on. — 100 to 200 bps increase per quarter, Q2FY27
• [TPA renewals] hold a potential of 5% to 7% jump on [Shalby hospital] revenue with the TPAs and other tie-ups. — 5% to 7%, FY27
• [Shalby] will manage with minimal CAPEX in FY27 and next year since [bunkers, robotics, MedTech] investments are done. — minimal CAPEX, FY28

Key themes

Margin recovery and MedTech scalability

How the narrative shifted

• Hospital margin recovery via occupancy and TPA: Management positions the margin dip as temporary, driven by new doctor ramp-ups and mix shift, with clear levers (bunkers, TPA renewals, unit performance) to drive margin above 20% for FY27.
• MedTech scalability and path to profitability: MedTech revenue up 53% YoY, EBITDA positive 4 quarters straight, cost-cutting initiatives projected to deliver double-digit margins; management frames it as building a high-margin, asset-light platform.
• Government payer mix shift and ARPOB pressure: Government scheme share rose to 32%, compressing ARPOB; management highlights rate revisions, super-specialty approvals, and CGHS accreditation to protect profitability and cash cycle.
• Capex moderation and ROCE enhancement: After heavy capex, the company will run with minimal capex, allowing EBITDA from Gurgaon and MedTech to flow through, targeting 11-13% consolidated ROCE within 1-2 years.
• International patient recovery and Gurgaon turnaround: Shalby International achieved EBITDA positive, 42% international revenue; occupancy at 24% expected to rise, PBT positive in 6-9 months, signalling turnaround of a previously underperforming asset.
• Inventory and working capital discipline in MedTech: MedTech inventory holding period declining, 30% improvement expected, reflecting working capital management; cash conversion remains a priority.

Operational commentary

• Shalby International (Gurgaon) achieved EBITDA breakeven for the first time since acquisition, with revenue ₹26.2 Cr, ARPOB ₹91,326, and 42% international revenue share; occupancy at 24%.
• Standalone hospital occupancy improved to 51% (excl Gurgaon), up from 45% last year, driven by 9.8% growth in occupied beds to 701.
• Hospital EBITDA margin compressed to 18.4% due to new doctor deployments and specialty ramp-ups; management expects margin recovery from Q2 as full contribution flows from these doctors and TPA renewals.
• MedTech India (SMTL) delivered strong volume growth (>100% YoY), with consolidated MedTech EBITDA positive for the fourth consecutive quarter; cost initiatives expected to reduce cash flow requirement by ₹3 Cr/month immediately and another ₹3 Cr/month by Q4FY27.
• Government payer mix increased to 32% (from 24% YoY), pressuring ARPOB, but super-specialty rate revision obtained at Krishna unit and CGHS accreditation at Gurgaon to mitigate impact.
• Bunker facilities activated; additional revenue and margin contribution expected in subsequent quarters.
• Key units Krishna, Mohali, Naroda posted ~30% YoY growth; Surat and Indore underperforming, doctor recruitment in progress.
• MedTech inventory holding period declining; management expects 30% reduction and 100-200 bps gross margin improvement per quarter.
• Capex peak behind; minimal capex expected in FY27-28, supporting ROCE improvement from 7% consolidated to 11-13% within 1-2 years.
• ICRA downgraded long-term rating to A (stable) from A+; management attributes to procedural assessment, replaced debt at 30 bps lower cost, net debt expected stable or lower.

Analyst Q&A

• Q. Can hospital margins sustain and improve further?

  Amit Kumar: We are confident to see improved margin from here; bunkers activated, more uptrend to come, new TPA renewals underway with 5-7% revenue upside, Shalby International posting EBITDA positive and improving, other units like Krishna, Mohali growing 30%, Surat/Indore doctor recruitment closing. Major part of revenue upside will flow to EBITDA.

• Q. Why did MedTech bottom line deteriorate despite revenue growth, and when will profitability improve?

  Shanay Shah: A large part of profitability decline was forex changes. Volumes grew significantly in India, US sales stable. Initiatives taken in Q1 will reduce cash flow requirement by ₹3 Cr/month, and a significant project by Q4 will cut another ₹3 Cr/month; we will achieve double-digit EBITDA margins after these changes, which take 6-12 months due to regulatory processes.

• Q. What is the timeline for Shalby International (Gurgaon) to achieve PBT breakeven and higher occupancy?

  Amit Kumar: We expect occupancy to touch 30% from Q3 or Q4 onwards, and we are confident of PBT positive by end Q3 or in 6-9 months; we already posted 7% EBITDA.

• Q. What drove ICRA long-term rating downgrade, and how is debt being managed?

  Amit Kumar: The rating moved to A with stable outlook from A+ with negative; it is a procedural assessment that could be upgraded in coming quarters. The recent ₹129 Cr facility is a replacement at 30 bps lower cost, not new debt; net debt will not increase and should remain stable or reduce.

• Q. How are you protecting cash conversion given the jump in government scheme share to 32%?

  Amit Kumar: We secured super-specialty rates at Krishna unit, and similar initiatives are underway; bunker treatments getting covered in government scheme; Gurgaon NABH/CGHS will bring better rates. For cash conversion, we deployed automated tools and processes for proactive follow-up on bill submissions and recoveries.

View source

Research and educational content only. Not investment advice.